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ALBUMINURIA PREDICTING OUTCOME IN HEART DISEASE
Effect of proteinuria and glomerular filtration rate on
cardiovascular risk in essential hypertension
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Effect of proteinuria and glomerular filtration rate on cardiovas-
cular risk in essential hypertension. Changes in renal function
related with essential hypertension are associated with an ele-
vated cardiovascular morbidity and mortality. Indices of altered
renal function (e.g., microalbuminuria, increased serum creati-
nine concentrations, decrease in estimated creatinine clearance
or GFR, and overt proteinuria) are independent predictors of
cardiovascular morbidity and mortality. The Framingham Heart
Study documented the relevance of proteinuria for cardiovascu-
lar prognosis in the community. The INSIGHT Study assessed
the role of proteinuria as a risk factor in essential hyperten-
sion. The presence of proteinuria at baseline turned out to be
a very potent predictor for the development of cardiovascular
events and death in patients with essential hypertension and
one or more associated cardiovascular risk factors. Recent data
indicate that minor derangements of renal function, including
proteinuria, are associated, both in the community and in the
hypertensive population, with the clustering of cardiovascular
risk factors observed in metabolic syndrome that promote pro-
gression of atherosclerosis. Renal function has to be routinely
evaluated in every hypertensive patient, and the presence of mi-
nor alterations considered in the stratification of cardiovascular
risk in hypertensive patients.
Evidence is accumulating that the kidney is not only a
target of the hypertensive process, but also contributes
to the development of cardiac and cerebral complica-
tions. Although in the laboratory, subtle changes in re-
nal function may be detected by measuring renal blood
flow or glomerular filtration rate (GFR), the practicing
clinician must rely on the determination of serum creati-
nine, creatinine clearance, and urinary albumin or protein
excretion. Several studies have shown that in essential hy-
pertension the presence of small amounts of albumin in
the urine (microalbuminuria) is an independent risk fac-
tor for future cardiovascular events [1]. Recent data indi-
cate that also serum creatinine acts as a marker of risk [2,
3]. Interestingly, the predictive power of serum creatinine
is independent from the finding of micro- or macroalbu-
minuria and demonstrable already with relatively normal
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values of this substance [3, 4]. Last year the Seventh Re-
port of the Joint National Committee (JNC-7) [5] rec-
ognized microalbuminuria and an estimated GFR below
60 mL/min/1.73m2 as major cardiovascular risk factors.
The European Society of Hypertension-European Soci-
ety of Cardiology (ESH-ESC) guidelines for the manage-
ment of arterial hypertension consider slight increase in
serum creatinine (1.3–1.5 mg/dL in men, 1.2–1.4 mg/dL in
women) and microalbuminuria as target organ damage,
and higher values of serum creatinine or the presence
of proteinuria as associated clinical conditions [6]. These
guidelines recommend measurement of serum creatinine
and estimation of GFR as routine tests in hypertensive
patients, and they also recommend the estimation of al-
buminuria [5, 6].
Diagnosis of renal damage in clinical practice
The diagnosis of renal dysfunction in patients with
different forms of cardiovascular disease is based on
two findings (i.e., elevated serum creatinine or a de-
crease in GFR) usually determined as estimated GFR
or creatinine clearance [7, 8], and/or the detection of an
elevated urinary excretion of albumin below (microalbu-
minuria, 30–300 mg/day) or above (macroalbuminuria,
>300 mg/day) the usual laboratory methods to detect
proteinuria. Chronic kidney disease (CKD) has recently
been defined as serum creatinine values above 1.5 mg/dL
(132 lmol/L) in men and 1.4 mg/dL (123 lmol/L) in
women [9], or by the finding of estimated GFR below
60 mL/min [2, 9]. While an elevated serum creatinine
concentration points to a reduced rate of glomerular fil-
tration, an increased rate of albumin or protein excre-
tion points to a derangement in the glomerular filtration
barrier [10]. Microalbuminuria has been shown to corre-
late with the presence of nephrosclerosis [11], while the
presence of proteinuria generally indicates the existence
of established renal parenchymatous damage [10]. On
the other hand, the finding of a serum creatinine value
within the normal range can be accompanied by a dimin-
ished GFR value, particularly in elderly patients [12]. The
presence of a diminished renal function is more prevalent
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Fig. 1. INSIGHT study showed that proteinuria is a very powerful car-
diovascular risk predictor, as an elevated serum creatinine or the exis-
tence of a previous myocardial infarction. Abbreviations: MI, myocar-
dial infarction; HTN, hypertension; TOD, target organ damage; HLP,
hyperlipidemia; SBP, systolic blood pressure; DBP, diastolic blood pres-
sure.
that previously thought in essential hypertension. This is
particularly so if estimated creatinine clearance is con-
sidered routinely in the evaluation of all hypertensive
patients [13].
Proteinuria and microalbuminuria as predictors
of cardiovascular risk
The relevance of proteinuria for CV prognosis in the
community was documented by the Framingham Heart
Study [14]. The presence of proteinuria in patients with
treated essential hypertension varies between 4% and
16% in different series of treated hypertensive patients
[15]. As in subjects with diabetic nephropathy, the pres-
ence of albuminuria or proteinuria in nondiabetic sub-
jects is independently associated with an increased CV
risk in longitudinal studies [3, 16–24]. The INSIGHT
study (International Nifedipine GITS study: Intervention
as a goal in Hypertension Treatment) compared the ca-
pacity of a long-acting dihydropiridine and a diuretic to
diminish cardiovascular events and death in essential hy-
pertension [25]. This study assessed the role of protein-
uria as an independent cardiovascular risk factor. The
analysis of the data revealed that proteinuria conferred
a very powerful risk similar to that accompanying an el-
evated serum creatinine or the existence of a previous
myocardial infarction (Fig. 1).
Attention has recently been drawn to microalbumin-
uria and its relevance as a predictor of cardiovascular
disease [26]. Its prevalence varies between 20% and 30%
of untreated patients and up to 25% in treated patients.
Very recently, it has been shown that the presence of
microalbuminuria in primary hypertension is associated
to an elevated CV risk [10, 27]. The risk is similar to
the one accompanying existing coronary artery disease.
According to a persuasive hypothesis, microalbuminuria
constitutes the renal expression of a generalized disor-
der characterized by increased endothelial permeability
[28–31], abnormalities of the fibrinolytic and coagulation
pathways, and activation of inflammatory process [32].
This hypothesis provides an explanation for the link be-
tween increased urinary albumin excretion (UAE) and el-
evated cardiovascular risk [26]. Some preliminary data in-
dicate that in primary hypertension, microalbuminuria is
also a predictor of progressive deterioration of renal func-
tion in primary hypertension [33, 34]. In the majority of
the published studies involving hypertensive patients, mi-
croalbuminuria was defined as a UAE between 30 and 300
mg/day. As used in the LIFE Study [35], a simpler alter-
native is the measurement of the albumin:creatinine ra-
tio in single morning first-void urine specimen (>3.5 mg/
albumin/mmol creatinine) for the diagnosis of microal-
buminuria. In patients with moderately severe hyper-
tension, this recent study showed that left ventricular
hypertrophy (LVH) is associated with increased preva-
lences of micro- and macroalbuminuria compared with
patients without LVH [35]. Furthermore, in the HOPE
study [16], the relative risk of the primary end point
in the fourth quartile was 1.97 (albumin:creatinine ratio
>1.62 mg/mmol) compared with the lowest quartile of al-
bumin:creatinine ratio. For every 0.4 mg/mmol increase
in albumin:creatinine ratio level, the adjusted hazard of
major cardiovascular events increases by 5.9% [16]. As
the data accumulate from the ongoing trials, and the nor-
mal range for urinary albumin excretion in hypertension
is better defined, the measurement of UAE rates may
serve a dual purpose. First, the presence of albuminuria
is a powerful way to identify those patients requiring an
integrated intervention on multiple cardiovascular risk
factors. Second, a failure to regress albumin excretion
in urine may indicate an inadequacy of that interven-
tion [36]. In this sense, Mann et al [37] have described
that in people at high cardiovascular risk, microalbumin-
uria predicts the development of clinical proteinuria in
nondiabetic and in diabetic people. Progression of al-
buminuria was found in one of five participants in the
4.5-year of follow-up in the HOPE trial. The progression
was seen in one of three patients with diabetes and in
one of seven without diabetes. This progression was ef-
fectively reduced was reduced by ACE inhibition in the
subgroups with and without diabetes.
Correlation of proteinuria and glomerular filtration rate
with cardiovascular risk
Both proteinuria and GFR are independent predictors
of CV morbidity and mortality. Reduced GFR is associ-
ated with a high prevalence of CV risk factors and a higher
prevalence of CV disease. Several studies across a broad
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Table 1. Cardiovascular risk factors or markers associated to a mild
decrease in estimated GFR (for review see [54])
Disturbed lipoprotein(a) concentrations
Insulin resistance and impaired glucose tolerance
Increased oxidate stress
Increment in pulse wave velocity
Increased serum uric acid levels
Sympathetic overactivity
Accumulation of ADMA
Inflammatory and procoagulant biomarkers
(CRP, fibrinogen, interleukin 6, factor VIIc, factor VIIIc,
plasmin-antiplasmin complex, and D-dimer)
Obesity and body fat distribution
Non-dipping pattern of ambulatory blood pressure
ADMA, asymmetric dimethylarginine; CRP, C-reactive protein.
spectrum of populations, such as the HOPE study [16],
the Cardiovascular Health Study (CHS) [38], the Hyper-
tension Optimal Treatment (HOT) Study [2], the Fram-
ingham and Framingham Offspring Studies [14, 39], and
the Atherosclerosis Risk in Communities (ARIC) study
[40], have shown that levels of systolic blood pressure,
total cholesterol, and the percentage of patients with low
HDL cholesterol are greater in subjects with decreased
GFR. Moreover, the percentages of subjects with dia-
betes, LVH, ischemic heart disease, and heart failure are
higher in those with decreased GFR [2, 14, 41–43]. Mild
degrees of renal failure have been shown to be associated
to a series of risk factors or markers that are summarized
in Table 1. A similar clustering of risk factors has been re-
ported in microalbuminuric subjects, in particular, those
linked to insulin resistance [44–48].
Reduced GFR is also associated with clinical CV out-
come in prospective studies. In high-risk populations,
most studies have suggested that decreased GFR is an
independent risk factor for outcomes. This is true in the
elderly, in whom even mild reductions of kidney function
are associated with worse outcomes [38], in studies of
hypertensive subjects [49], in hypertensive patients with
baseline normal renal function and development of hy-
pertensive nephrosclerosis during their follow-up [50], in
population studies with higher than normal prevalence of
diabetes [50], and among older patients undergoing gen-
eral surgery [52]. In low-risk populations or community-
based studies, the relationship between the level of
kidney function and outcomes has not been as clear.
Discrepancies in the studies include differences in the
study populations, and alternate measures of kidney func-
tion, considering that serum creatinine is less sensitive
than estimated GFR to detect small differences in level
of kidney function [13]. In any case, the association of
reduced GFR and CV risk is supported by evidence
showing the relationship between reduced GFR and
nontraditional CV risk factors that frequently are not
assessed [53]. Reduced GFR may then be a marker of un-
diagnosed vascular disease, or alternatively, a marker for
the severity of diagnosed vascular disease [54]. Moreover,
recent data have suggested that patients with reduced
Table 2. Prevalence of microalbuminuria and proteinuria according
to estimated glomerular filtration rate (GFR)
Estimated GFR
(mL/min/1.73m2) N (%) Microalbuminuria % Proteinuria %
>90 680 (65) 31.9 3.5
60–90 240 (23) 30.2 5.0
<60 127 (12) 37.6 10.2
Total 1047 31.3 4.7
GFR are less likely to receive medications or therapies,
such as angiotensin-converting enzyme inhibitors, beta-
blockers, aspirin, platelet inhibitors, thrombolytics, or
percutaneous intervention than patients with preserved
GFR [55–57].
Definitely, both proteinuria and reduced GFR are as-
sociated with an increased CV risk. Nevertheless, it is
not well established the percentage of patients present-
ing both disturbances. We have analyzed the prevalence
of microalbuminuria and proteinuria according to GFR
values in a cohort of 1047 essential hypertensive patients
attended in a hospital located hypertension unit. As can
be seen in Table 2, the prevalences of microalbuminuria
and proteinuria increase significantly at estimated GFR
values below 60 mL/min/1.73m2. Both microalbuminuria
and proteinuria were significantly associated with lower
values of estimated GFR, diabetes mellitus, male gen-
der, age above 60 years, and the presence of target organ
damage or associated clinical conditions. These findings
contribute to explain the exponential increase in CV risk
observed with progressive decay in renal function.
Microalbuminuria could be present in hypertensive pa-
tients with preserved GFR, including those presenting
hyperfiltration as an early marker of renal dysfunction.
Urinary albumin excretion would increase progressively
in association with an increased severity of hypertension
and with the progressive decay in GFR values, as can be
seen in Figure 2.
Simultaneous correction or prevention of renal
and cardiovascular damage is required
Table 3 summarizes the therapeutic attitudes that must
be considered in presence of CKD. They contemplate the
simultaneous performance of cardiovascular and renal
protection. Lifestyle changes, with particular emphasis on
diminishing salt intake, avoiding obesity, and refraining
from smoking are very important. Strict blood pressure
control (probably below 125/75 mm Hg in every patient)
is required, and the administration of a combination of
drugs needed [5, 6]. The presence of an angiotensin-
converting enzyme inhibitor or an angiotensin receptor
blocker is required because blockade of angiotensin II
effects has demonstrated to improve the long-term re-
nal outcome of patients with nephrosclerosis [58, 59].
The role of dual blockade of renin-angiotensin system
combining an angiotensin-converting enzyme inhibitor
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Fig. 2. Relationship among severity of hyper-
tension, cardiovascular and renal risk, and the
presence of chronic kidney disease and in-
creased urinary albumin excretion.
Table 3. Therapeutic attitudes in patients with chronic kidney disease
and hypertension
Lifestyle changes
(Salt intake, body weight, and stop smoking)
Strict blood pressure control
(<125/75 mm Hg): Combination therapy required in most cases.
ACE inhibitor or ARB is required
Control of associated risk factors
Lipids: statins, fibrates
Insulin resistance: insulin sensitizers (metformin, glitazones?)
Platelet aggregation: aspirins, others?
and an angiotensin receptor blocker remains to be elu-
cidated in essential hypertensive patients, albeit it has
demonstrated its efficacy in primary renal disease accom-
panied by proteinuria [60].
The presence of CKD, manifested as albuminuria
and/or reduced GFR, appears to be an independent CV
risk factor, particularly in higher-risk populations. Ac-
cording to the National Kidney Foundation task force
recommendation, patients with CKD should be consid-
ered in the highest risk group for CV events [9]. The JNC-
7 includes CKD as a “compelling” indication, justifying
lower target blood pressure and treatment with specific
antihypertensive agents [5]. Similarly, the recently pub-
lished “NKF-K/DOQI Clinical Practice Guidelines on
Managing Dyslipidemia in Chronic Kidney Disease” rec-
ommend that all patients with CKD be included in the
highest risk group, justifying a lower target low-density
lipoprotein cholesterol level [61]. The American Heart
Association suggests that the routine evaluation of pa-
tients with CV disease, or those at high CV risk, should
include measurement of spot urine albumin-to-creatinine
ratio or total protein-to-creatinine ratio and estimation of
GFR by serum creatinine and prediction equations [54].
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